← Leaderboards
Chris Scott
State University Of New York At Buffalo
$539,205
Attributed
$2,156,820
Total exposure
1
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $452.2K · FY2015–19$500K$375K$250K$125K$0
'15
'16
'17
'18
'19
Funding mix
By agency
NIH$2,156,820 · 1
By mechanism
R01$2,156,820 · 1
Top collaborators
- Wen Wee Ma5 shared
- Robert M Straubinger5 shared
- Niall Barron3 shared
- Martin Clynes2 shared
Most similar at State University Of New York At Buffalo
Same institution · by research overlap
- Robert M Straubinger$4,875,752
- Wen Wee Ma$737,204
- Jun Xia$3,270,650
- Chong Cheng$2,440,190
- Niall Barron$327,737
Others in their field
Top investigators on “Disease Progression”
- Lawrence Corey · Fred Hutchinson Cancer Center$405,086,239
- Constance Ann Benson · University Of California, San Diego$244,117,339
- Jeffrey P Krischer · University Of South Florida$225,151,653
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$157,315,120
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$150,116,206
- Peter B. Gilbert · Fred Hutchinson Cancer Center$146,027,526
Research focus
Disease ProgressionDrug CarriersBloodDiagnosisBaseBlood VesselsCancer BiologyCancer CellAffinityCancer TherapyCetuximabCharacteristicsChemotherapyClinical DataClinically RelevantClinical TrialsCombined Modality TherapyComplexCytotoxicityBlood FlowDensityDepositionDesignDrug Delivery Systems
Grant awards (5)
Tumor priming sequences combined with novel nanoparticle drug carriers for enhanced therapeutic efficacy in pancreatic cancer: a tripartite USA/Northern Ireland/Republic of Ireland consortium$416,494
R01 · FY2019 · CA
Tumor priming sequences combined with novel nanoparticle drug carriers for enhanced therapeutic efficacy in pancreatic cancer: a tripartite USA/Northern Ireland/Republic of Ireland consortium$429,377
R01 · FY2018 · CA
Tumor priming sequences combined with novel nanoparticle drug carriers for enhanced therapeutic efficacy in pancreatic cancer: a tripartite USA/Northern Ireland/Republic of Ireland consortium$429,377
R01 · FY2017 · CA
Tumor priming sequences combined with novel nanoparticle drug carriers for enhanced therapeutic efficacy in pancreatic cancer: a tripartite USA/Northern Ireland/Republic of Ireland consortium$429,377
R01 · FY2016 · CA
Tumor priming sequences combined with novel nanoparticle drug carriers for enhanced therapeutic efficacy in pancreatic cancer: a tripartite USA/Northern Ireland/Republic of Ireland consortium$452,195
R01 · FY2015 · CA